Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA plus CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study

Basit Öğe Kaydı
dc.authoridMoreno, Victor/0000-0002-2818-5487
dc.authorwosidMoreno, Victor/A-1697-2010
dc.contributor.authorSiefker-Radtke, Arlene O.
dc.contributor.authorPowles, Thomas
dc.contributor.authorMoreno, Victor
dc.contributor.authorKang, Taek Won
dc.contributor.authorCicin, Irfan
dc.contributor.authorGirvin, Angela
dc.contributor.authorAkapame, Sydney
dc.date.accessioned2024-06-12T11:24:00Z
dc.date.available2024-06-12T11:24:00Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 02-06, 2023 -- Chicago, ILen_US
dc.description.abstract[Abstract Not Available]en_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.description.sponsorshipJanssen Research Developmenten_US
dc.description.sponsorshipJanssen Research & Development.en_US
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26770
dc.identifier.volume41en_US
dc.identifier.wosWOS:001053772000991en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal Of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleErdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA plus CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse studyen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu